Skip to main content
SpringerLink
Log in

Prevalence of depressive syndrome in patients with breast cancer treated with or without aromatase inhibitors

Prévalence du syndrome dépressif chez des patientes traitées pour un cancer du sein avec ou sans antiaromatases

  • Review / Revue
  • Published:
Oncologie

Abstract

Aims

Women with breast cancer are at higher risk of suffering from a depressive syndrome.We aim to observe the prevalence of depressive syndrome in patients with breast cancer treated with aromatase inhibitors (AI) and in a control group without hormonal therapy.

Materials and methods

We use self-assessment scales, including the Beck Depression Inventory, in the two groups of patients.

Results

54 patients were included in the AI group and 16 patients in the control group. We registered 11.1% of moderate to severe depressive syndrome in the AI group vs. 37.5% in the control group.

Conclusion

We can consider these results as preliminary to further studies to highlight a link between AI and depressive syndrome. Other studies with biggest populations are necessary to establish a link between AI and depression.

Résumé

Objectif

Observation de la prévalence du syndrome dépressif chez des patientes sous antiaromatases (AA) en traitement du cancer du sein, et dans un groupe témoin sans hormonothérapie.

Matériel et méthodes

Utilisation d’échelles d’autoévaluation, dont l’échelle de Beck.

Résultats

Cinquante-quatre patientes sont incluses dans le groupe AA, 16 patientes dans le groupe témoin. 11,1 % des patientes sous AA ont un syndrome dépressif d’intensité modérée à sévère, alors qu’elles sont 37,5 % dans le groupe témoin.

Conclusion

Ce travail amène des résultats préliminaires en vue d’études supplémentaires pour rechercher un lien entre AA et syndrome dépressif.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lemperiere T (2003) Dépression et comorbidités somatiques. PRID (Programme de Recherche et d’Information sur la Dépression). Masson, Issy-les-Moulineaux, 259 p

    Google Scholar 

  2. de Cremoux P, Dieras V, Poupon MF, et al. (2004) Le tamoxifène et les inhibiteurs d’aromatase dans le traitement des cancers du sein: aspects pharmacologiques et cliniques. Bull Cancer 91: 917–27

    PubMed  Google Scholar 

  3. Stahl SM (2010) Psychopharmacologie essentielle. 2nd édition. Lavoisier, Paris, 1116 p

    Google Scholar 

  4. Cuzick J, Sestak I, Baum M, et al. (2010) Effects of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10 years analysis of the ATAC trial. Lancet Oncol 11: 1135–41

    Article  PubMed  CAS  Google Scholar 

  5. Howell A, Cuzick J, Baum M, et al. (2005) Results of the ATAC trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 365: 60–2

    Article  PubMed  CAS  Google Scholar 

  6. Day R, Ganz PA, Costantino J (2001) Tamoxifen and depression: more evidence from the national surgical adjuvant breast and bowel project’s breast cancer prevention (P-1) randomized study. J Natl Cancer Inst 93: 1615–23

    Article  PubMed  CAS  Google Scholar 

  7. Takei H, Ohsumi S, Shimozuma K, et al. (2012) Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat 133: 227–36

    Article  PubMed  CAS  Google Scholar 

  8. Ribi K, Aldridge J, Phillips KA, et al. (2012) Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 106: 1618–25

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Taira N, Iwata H, Hasegawa Y, et al. (2014) Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. Breast Cancer Res Treat 145: 155–64

    Article  PubMed  CAS  Google Scholar 

  10. Jenkins VA, Ambroisine LM, Atkins LM, et al. (2008) Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol 9: 953–61

    Article  PubMed  CAS  Google Scholar 

  11. Goss PE, Ingle JN, Ales-Martinez JE, et al. (2011) Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 364: 2381–91

    Article  PubMed  CAS  Google Scholar 

  12. van Nes JGH, Fontein DBY, Hille ETM, et al. (2012) Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a tamoxifen exemestane adjuvant multinational (TEAM) Trial side study. Breast Cancer Res Treat 134: 267–76

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Mao JJ, Farrar JT, Bruner D, et al. (2014) Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitors-related arthralgia: a randomized trial. Cancer 120: 3744–51

    Article  PubMed  PubMed Central  Google Scholar 

  14. de Bock GH, Musters RF, Bos HJ, et al. (2012) Psychotropic medication during endocrine treatment for breast cancer. Support Care Cancer 20: 1533–40

    Article  PubMed  PubMed Central  Google Scholar 

  15. Niravath P, Rimawi MF, Osborne CK (2014). Aromatase inhibitors adverse effects: are we sweeping them under the rug? J Clin Oncol 32: 3779

    Article  PubMed  Google Scholar 

  16. Seliktar N, Polek C, Brooks A, Hardie TP (2014) Cognition in breast cancer survivors: hormones versus depression. Psychooncology 24: 402–7; online version

    Article  PubMed  Google Scholar 

  17. Ganz PA, Petersen L, Castellon SA, et al. (2014) Cognitive function after the initiation of adjuvant endocrine therapy in early breast cancer: an observational cohort study. J Clin Oncol 32: 3559–67

    Article  PubMed  PubMed Central  Google Scholar 

  18. Pandey M, Sarita GP, Devi N, et al. (2006) Distress, anxiety and depression in cancer patients undergoing chemotherapy. World J Surg Oncol 4: 68

    Article  PubMed  PubMed Central  Google Scholar 

  19. Beck AT, Steer RA, Garbin MG (1988) Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 8: 77–100

    Article  Google Scholar 

  20. Joly F, Lange M, Rigal O, et al. (2012) French version of the functional assessment of cancer therapy-cognitive function (FACT-Cog) version 3. Support Care Cancer 20: 3297–305

    Article  PubMed  CAS  Google Scholar 

  21. Von ah D, Habermann B, Carpenter JS, Schneider BL (2013) Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 17: 236–41

    Google Scholar 

  22. Rakovitch E, Franssen E, Kim J, et al. (2003) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77: 285–93

    Article  PubMed  Google Scholar 

  23. Bardwell WA, Natarajan L, Dimsdale JE, et al. (2006) Objective cancer-related variables are not associated with depressive symptoms in women treated for early-stage breast cancer. J Clin Oncol 24: 2420–7

    Article  PubMed  Google Scholar 

  24. Iwatani T, Matsuda A, Kawabata H, et al. (2013) Predictive factors for psychological distress related to diagnosis of breast cancer. Psychooncology 22: 523–9

    Article  PubMed  Google Scholar 

  25. Laroche F, Coste J, Medkour T, et al. (2014) Classification and risk factors for aromatase inhibitor pain syndromes: a prospective multicentre cohort study. J Pain 15: 293–303

    Article  PubMed  CAS  Google Scholar 

  26. Stellman SD, Soskolne CL (2000) Encyclopédie de sécurité et de santé du travail. In: Chap 28: Les questionnaires en recherche épidémiologique. International Labour Organization, 4838 p

    Google Scholar 

  27. Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73: 156–66

    Article  PubMed  Google Scholar 

  28. Burgess C, Cornelius V, Love S, et al. (2005) Depression and anxiety in women with early breast cancer: five years observational cohort study. BMJ 330: 702–5

    Article  PubMed  PubMed Central  Google Scholar 

  29. Fann JR, Thomas Rich AM, Katon WJ, et al. (2008) Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 30: 112–26

    Article  PubMed  Google Scholar 

  30. Maunsell E, Goss PE, Chlebowski RT, et al. (2014) Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebocontrolled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 32: 1427–36

    Article  PubMed  Google Scholar 

  31. Kirk MC, Hudis CA (2008) Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 8: 155–61

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service hospitalo-universitaire du Professeur Terra Hôpital du Vinatier, 95, boulevard Pinel, F-69500, Bron, France

    A. Couillet

  2. Centre Léon-Bérard, 28, rue Laennec, F-69373, Lyon cedex 08, France

    O. Tredan, N. Oussaid & P. Saltel

Authors
  1. A. Couillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Tredan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Oussaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Saltel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to A. Couillet, O. Tredan, N. Oussaid or P. Saltel.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Couillet, A., Tredan, O., Oussaid, N. et al. Prevalence of depressive syndrome in patients with breast cancer treated with or without aromatase inhibitors. Oncologie 17, 587–594 (2015). https://doi.org/10.1007/s10269-015-2573-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-015-2573-5

Keywords

Mots clés

Search

Navigation